%0 Journal Article
%T Clearance of pediatric actinic prurigo with dupilumab.
%A Eickstaedt JB
%A Starke S
%A Krakora D
%A Hinshaw M
%A Arkin LM
%J Pediatr Dermatol
%V 37
%N 6
%D Nov 2020
%M 32869345
%F 1.997
%R 10.1111/pde.14311
%X Actinic prurigo is a rare, idiopathic chronic photodermatosis of childhood characterized by excoriated papules, nodules, and plaques in sun-exposed areas. It is notoriously difficult to treat. The disorder involves a type IV hypersensitivity reaction driven by both Th1 and Th2 inflammatory pathways, the latter of which leads to secretion of IL-4, IL-5, IL-13, and production of B cells, IgE, and IgG4. Dupilumab, an IL-4 receptor antagonist, disrupts the Th2 pathway. We present a pediatric patient with severe, recalcitrant actinic prurigo who achieved rapid and sustained clearance with dupilumab.